Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients

Table 1

Demographic data and clinical measures.

Parameter	ESRD and HCV	HCV^+	ESRD	HC
Gender
Men	18	9	13	12
Women	22	11	7	8
Age (years ± SE)	55.2 ± 1.47	53.8 ± 2.32	55.6 ± 2.84	52.9 ± 1.67
Dialysis (years ± SE)	13.8 ± 1.26	—	3.85 ± 0.34	—
HCV status (years ± SE)	7.02 ± 0.67	8.25 ± 1.04	—	—

(Mann–Whitney test).